Our collaborators

The Institute of Cancer Research collaborates with industrial, academic and hospital partners over a range of projects – from drug discovery programmes and biomarker studies, to the development of high intensity focussed ultrasound for the treatment of cancer.

Some of our recent collaborations have included:

Astex – a 3.5-year drug discovery collaboration aimed at identifying a preclinical candidate which inhibits the molecule MMSET.

AstraZeneca – a range of programmes and projects under a strategic alliance

BACIT – co-investment alongside Sareum and the CRT Pioneer Fund in the Chk1 drug development programme

CRT Pioneer Fund – a series of 4 collaboration and licence agreements on drug discovery programme

Domainex – providing chemistry support on a 5-year drug discovery collaboration funded by the Wellcome Trust

Elekta – a range of projects in the field of radiotherapy and imaging

Enzon pharmaceuticals – a biomarker collaboration 

Horizon – collaboration to identify synthetic lethal cancer targets using Horizon’s isogenic cell lines

Illumina, Inc. – collaborative development of a cancer susceptibility genetic screening panel – TruSight Cancer

Janssen – a 2.5-year drug discovery collaboration

Merck – a multi-programme drug discovery collaboration

Nuevolution – a drug discovery collaboration working on difficult to drug targets

Onyx – a clinical trial of a novel α-folate receptor-mediated thymidylate synthase inhibitor using a study drug that was developed at ICR

Phillips – A collaboration in the field of High Intensity Focused Ultrasound (HIFU) treatment aiming to evaluate and optimise novel applications of HIFU in the treatment of cancer

Ventana – a multi-program collaboration providing equipment and support for a number of projects

Other industrial collaborators include: Amgen, EMD Millipore, Genentech, GSK, Morphosys, Oncolytics, PreCOS, Roche, Sanofi Aventis, Symphogen and Teva.

 

 

Related news

Related blogs

Headshot of Agnieszka Konopacka in front of an ICR building

19/02/25 - Robbie Lockyer

Dr Agnieszka Konopacka recently joined The Institute of Cancer Research, London, as Group Leader of the Induced Proximity Therapeutics Group, which sits within the Centre for Protein Degradation in the Division of Cancer Therapeutics. By exploring innovative drug discovery approaches based on targeted protein degradation, her team is looking to find new ways to defeat cancer. Robbie Lockyer spoke with her to learn more.